Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial

Conclusion
In patients with a history of MI, patients with renal dysfunction are at increased risk of MACE and consequently experience a particularly robust absolute risk reduction with long-term treatment with ticagrelor.

Source: European Heart Journal - January 21, 2016 Category: Cardiology Authors: Magnani, G., Storey, R. F., Steg, G., Bhatt, D. L., Cohen, M., Kuder, J., Im, K., Aylward, P., Ardissino, D., Isaza, D., Parkhomenko, A., Goudev, A. R., Dellborg, M., Kontny, F., Corbalan, R., Medina, F., Jensen, E. C., Held, P., Braunwald, E., Sabatine, Tags: Thrombosis and antithrombotic therapy Source Type: research